Clinical Trial

A Study of Lebrikizumab in Adults With Nummular Eczema

Study acronym: LUMINE
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or when this treatment is not medically advisable.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-15.
Trial Details
NCT Number NCT07542483
Lead Sponsor Almirall, S.A.
Conditions Nummular Eczema
Enrollment 270 participants
Start Date 2026-04
Primary Completion 2028-08 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-14